View of Outcomes of Patients Treated with Brentuximab Vedotin in Relapsed or Refractory CD30 Positive Lymphomas; A Single Center Experience

Return to Article Details Outcomes of Patients Treated with Brentuximab Vedotin in Relapsed or Refractory CD30 Positive Lymphomas; A Single Center Experience Download Download PDF